Supplementary Material

Authors: Kristina T. Kumpf, MA; Samuel T. Wilkinson, MD; Bo Hu, PhD; Ruoying Chen, PhD; Kamini Krishnan, PhD; Shinjon Chakrabarti, BS; Taeho Greg Rhee, PhD; Tiffany Grezmak, MA; Sanjay J. Mathew, MD; Gerard Sanacora, MD, PhD; James W. Murrough, MD, PhD; Fernando S. Goes, MD; Katherine A. Collins, PhD, LCSW; Brian S. Barnett, MD; Amit Anand, MD

LIST OF SUPPLEMENTARY MATERIAL FOR THE ARTICLE

DISCLAIMER

This Supplementary Material has been provided by the authors as an enhancement to the published article. It has been approved by peer review; however, it has undergone neither editing nor formatting by in-house editorial staff. The material is presented in the manner supplied by the author.

Supplementary Figure 1[a]

Supplementary Figure 1 Caption.

[a] Mixed-effect model of ordinary least-square means showing change in cognitive task performance among responders from baseline through end of treatment (EOT), and follow-up visits at 1 month, 3 months, and 6 months following the completion of treatment. Baseline MoCA represents score at screening visit. Analysis included responders to ECT (N=70) and ketamine (N=108), where response was defined as achieving a ≥50% reduction in QIDS-SR-16 scores. Figure a shows change in performance on the Controlled Oral Word Association Test (COWAT), Figure b shows change in performance on the Hopkins Verbal Learning Test Revised – delayed recall (HVLT-R delayed recall), Figure c shows change in performance on the Hopkins Verbal Learning Test Revised – Total Score (HVLT-R total), Figure d shows change in performance on the Montreal Cognitive Assessment (MoCA), Figure e shows change in performance on the Stroop Interference Condition (Stroop). For all tasks higher scores indicate better performance.

False discovery rate adjusted significance indicated by * (p<0.001)

Supplementary Table 1. Demographic and clinical factors of the sample by treatment response [a] (N=365)		Mean / no. (SD / %)		
		Non-Responders (N = 187)	Responders (N = 178)	SMD
Age – years		46.49 (14.55)	45.58 (14.48)	0.063
Education – years		15.46 (2.46)	15.71 (2.71)	0.096
Female – no. (%)[b]		95 (50.8)	96 (53.9)	0.063
Racial Identity – no. (%)[b]				0.32
	African American	15 (8.0)	5 (2.8)	
	White	154 (82.4)	165 (92.7)	
	Other	18 (9.6)	8 (4.5)	
Non- Hispanic Identity – no. (%)[b]		172 (92.0)	162 (91.0)	0.035
BMI		29.70 (7.41)	30.18 (7.85)	0.062
Comorbidities – no. (%)				
	GAD	97 (51.9)	103 (57.9)	0.121
	PTSD	36 (19.3)	44 (24.7)	0.132
	OCD	14 (7.5)	10 (5.6)	0.076
	Substance Use	13 (7.0)	9 (5.1)	0.08
Age at onset of first depressive episode - years		19.78 (12.16)	19.02 (10.53)	0.067
Baseline QIDS		18.08 (4.20)	18.05 (4.04)	0.007
Baseline MADRS		32.86 (6.06)	32.11 (6.18)	0.121
Baseline Cognitive Performance				
	NAART-35 Standard Score	88.29 (8.92)	89.06 (10.17)	0.08
	MoCA Total Score	26.44 (2.67)	26.82 (2.61)	0.142
	HVLT-R Delayed Recall	38.72 (14.81)	38.28 (14.48)	0.03
	HVLT-R Total Score	35.89 (13.30)	36.45 (12.93)	0.043
	COWAT	36.95 (10.27)	38.77 (11.40)	0.167
	Stroop Word Reading Total Score	85.19 (17.94)	90.04 (17.72)	0.272
	Stroop Color Reading Total Score	62.09 (12.70)	65.08 (12.69)	0.235
	Stroop Interference Total Score	37.95 (11.19)	39.82 (11.28)	0.166

Concomitant Psychiatric Medications – no. (%)			
Antidepressants	159 (85.0)	147 (82.6)	0.066
Benzodiazepines	59 (31.6)	55 (30.9)	0.014
Anticonvulsants	48 (25.7)	49 (27.5)	0.042
Antipsychotics	51 (27.3)	54 (30.3)	0.068
Lithium	25 (13.4)	17 (9.6)	0.12

[a] Response was considered ≥50% improvement on QIDS-SR-16 to either treatment at end of treatment visit.

[b] Data is derived from participant self-report.

SMD = Standard Mean Difference